Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. on June 25, 2018. The report addresses a regulatory update concerning the Company's pegfilgrastim biosimilar product candidate, CHS-1701, involving the Committee for Medicinal Products for Human Use (CHMP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements.
Material Changes
On June 25, 2018, the CHMP issued a draft agenda indicating that further interactions with Coherus are required to address outstanding issues regarding CHS-1701 before a CHMP opinion can be rendered. No pre-authorization oral explanation has been requested by the CHMP to date.
Guidance, Outlook, and Risks
- Outlook: The Company anticipates the required interactions will occur prior to the next CHMP meeting scheduled for July 23 to 26, 2018.
- Next Opportunity: The July 23-26 meeting is understood to be the next opportunity for the CHMP to issue an opinion on the product candidate.
- Risks: The delay in rendering an opinion introduces uncertainty regarding the timeline for regulatory approval of CHS-1701 in the European Union.
Investor Verification Checklist
- Verify the specific nature of the "outstanding issues" raised by the CHMP regarding CHS-1701.
- Monitor the outcome of the anticipated interactions prior to the July 23, 2018 CHMP meeting.
- Confirm whether the July 23-26 meeting results in a positive, negative, or deferred CHMP opinion.